UK's Latest Cancer Drug Cull Draws Renewed Calls For Reform
This article was originally published in Scrip
New cuts to publicly funded NHS oncology treatments announced in Britain have triggered fresh criticisms of the government's Cancer Drugs Fund and renewed calls for a system-wide overhaul of the way cancer drugs are commissioned in the country.
You may also be interested in...
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.